Europe Human Insulin Market Size- By Type, By Diabetes Type, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

Introduction and Overview

According to SPER Market Research, 'Europe Human Insulin Market Size- By Type, By Diabetes Type, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Europe Human Insulin Market is predicted to reach with a CAGR of 1.7%.

The protein hormone insulin that is produced by the human pancreas is prepared pharmaceutically as insulin. It manages blood glucose (sugar) levels, modulates amino acid absorption by body cells, and governs the metabolism of lipids, proteins, and carbs. Diabetes is a chronic illness characterised by an excess of blood sugar in the bloodstream due to insufficient insulin production by the body or a failure of the cells to respond to insulin.

Furthermore, because of COVID-19, the supply chain for the raw ingredients required to produce pharmaceuticals and human insulin delivery systems has been disrupted in a number of nations. Furthermore, as fewer human insulin is being produced by manufacturers of these medications and devices, the outbreak is contracting the market for the substance.

Scope of the Report

Report Metric Details:

Market size available for years: 2019-2033

Base year considered: 2022

Forecast period: 2023-2033

Segments covered: By Type, By Diabetes Type, By Distribution Channel

Regions covered: France, Germany, Italy, Scandinavia, Spain, U.K., and rest of Europe

Companies Covered: ADOCIA, B. Braun Melsungen AG, Biocon, BIOTON S.A., Eli Lilly and Company, Lupin, Novo Nordisk A/S, Sanofi, WOCKHARDT, Others

Market Segmentation:

By Type: Based on the Type, Europe Human Insulin Market is segmented as; Analogue Insulin (Fast-acting, Long-acting, Premix), Traditional Human Insulin (Fast-acting, Long-acting + Intermediate, Premix, Short-acting).

By Distribution Channel: Based on the Distribution Channel, Europe Human Insulin Market is segmented as; Hospital Pharmacies, Retail & Online Pharmacies.

By Region: This research also includes data for France, Germany, Italy, Scandinavia, Spain, U.K., and rest of Europe.

Product Code: PHAR2315

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data Source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Europe Human Insulin Market

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Europe Human Insulin Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe Human Insulin Market

7. Europe Human Insulin Market, By Type (USD Million)

7.1. Europe Human Insulin Market Value Share and Forecast, By Type, 2023-2033
7.2. Analogue Insulin
- 7.2.1. Fast-acting
- 7.2.2. Long-acting
- 7.2.3. Premix
7.3. Traditional Human Insulin
- 7.3.1. Fast-acting
- 7.3.2. Long-acting + Intermediate
- 7.3.3. Premix
- 7.3.4. Short-acting

8. Europe Human Insulin Market, By Diabetes Type (USD Million)

8.1. Europe Human Insulin Market Value Share and Forecast, By Diabetes Type, 2023-2033
8.2. Diabetes 1
8.3. Diabetes 2

9. Europe Human Insulin Market, By Distribution Channel (USD Million)

9.1. Europe Human Insulin Market Value Share and Forecast, By Distribution Channel, 2023-2033
9.2. Hospital Pharmacies
9.3. Retail & Online Pharmacies

10. Europe Human Insulin Market Forecast, 2019-2033 (USD Million)

10.1. Europe Human Insulin Market Size and Market Share

11. Europe Human Insulin Market, By Type, 2019-2033 (USD Million)

11.1. Europe Human Insulin Market Size and Market Share By Type (2019-2026)
11.2. Europe Human Insulin Market Size and Market Share By Type (2027-2033)

12. Europe Human Insulin Market, By Diabetes Type, 2019-2033 (USD Million)

12.1. Europe Human Insulin Market Size and Market Share By Diabetes Type (2019-2026)
12.2. Europe Human Insulin Market Size and Market Share By Diabetes Type (2027-2033)

13. Europe Human Insulin Market, By Distribution Channel, 2019-2033 (USD Million)

13.1. Europe Human Insulin Market Size and Market Share By Distribution Channel (2019-2026)
13.2. Europe Human Insulin Market Size and Market Share By Distribution Channel (2027-2033)

14. Europe Human Insulin Market, By Region, 2019-2033 (USD Million)

14.1. Europe Human Insulin Market Size and Market Share By Region (2019-2026)
14.2. Europe Human Insulin Market Size and Market Share By Region (2027-2033)
14.3. France
14.4. Germany
14.5. Italy
14.6. Scandinavia
14.7. Spain
14.8. U.K.
14.9. Rest of Europe

15. Company Profile

15.1. ADOCIA
- 15.1.1. Company details
- 15.1.2. Financial outlook
- 15.1.3. Product summary
- 15.1.4. Recent developments
15.2. B. Braun Melsungen AG
- 15.2.1. Company details
- 15.2.2. Financial outlook
- 15.2.3. Product summary
- 15.2.4. Recent developments
15.3. Biocon
- 15.3.1. Company details
- 15.3.2. Financial outlook
- 15.3.3. Product summary
- 15.3.4. Recent developments
15.4. BIOTON S.A.
- 15.4.1. Company details
- 15.4.2. Financial outlook
- 15.4.3. Product summary
- 15.4.4. Recent developments
15.5. Eli Lilly and Company
- 15.5.1. Company details
- 15.5.2. Financial outlook
- 15.5.3. Product summary
- 15.5.4. Recent developments
15.6. Lupin
- 15.6.1. Company details
- 15.6.2. Financial outlook
- 15.6.3. Product summary
- 15.6.4. Recent developments
15.7. Novo Nordisk A/S
- 15.7.1. Company details
- 15.7.2. Financial outlook
- 15.7.3. Product summary
- 15.7.4. Recent developments
15.8. Sanofi
- 15.8.1. Company details
- 15.8.2. Financial outlook
- 15.8.3. Product summary
- 15.8.4. Recent developments
15.9. WOCKHARDT
- 15.9.1. Company details
- 15.9.2. Financial outlook
- 15.9.3. Product summary
- 15.9.4. Recent developments
15.10. Others